 | • レポートコード：MRC2012A5141 • 出版社/出版日：GlobalInfoResearch / 2020年12月21日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品、医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、静脈内（IV）鉄剤の世界市場を広く調査・分析し、今後の市場展望をまとめております。静脈内（IV）鉄剤の種類別市場規模（カルボキシマルトース鉄、鉄スクロース、鉄デキストラン、その他）、用途別市場規模（腎臓内科、婦人科・産科、消化器内科、腫瘍内科、循環器内科、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：Sanofi US、Dalichi Sankyo、Allergan、Takeda Pharmaceutical、AMAG Pharmaceuticals、Pharmacosmos、Luitpold Pharmaceuticals、 ・地域別グローバル市場分析 2015年-2020年 ・静脈内（IV）鉄剤の北米市場（アメリカ、カナダ、メキシコ） ・静脈内（IV）鉄剤のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・静脈内（IV）鉄剤のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・静脈内（IV）鉄剤の南米市場（ブラジル、アルゼンチン） ・静脈内（IV）鉄剤の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：カルボキシマルトース鉄、鉄スクロース、鉄デキストラン、その他 ・用途別分析：腎臓内科、婦人科・産科、消化器内科、腫瘍内科、循環器内科、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Intravenous (IV) Iron Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.9% in the forecast period of 2020 to 2025 and will expected to reach USD 1716.1 million by 2025, from USD 1472.2 million in 2019.
The Intravenous (IV) Iron Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Intravenous (IV) Iron Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Intravenous (IV) Iron Drugs market has been segmented into
Ferric Carboxymaltose
Iron Sucrose
Iron Dextran
Others
By Application, Intravenous (IV) Iron Drugs has been segmented into:
Nephrology
Gynecology & Obstetrics
Gastroenterology
Oncology
Cardiology
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Intravenous (IV) Iron Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Intravenous (IV) Iron Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Intravenous (IV) Iron Drugs market.
The report offers in-depth assessment of the growth and other aspects of the Intravenous (IV) Iron Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Intravenous (IV) Iron Drugs Market Share Analysis
Intravenous (IV) Iron Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Intravenous (IV) Iron Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Intravenous (IV) Iron Drugs sales, revenue and market share for each player covered in this report.
The major players covered in Intravenous (IV) Iron Drugs are:
Sanofi US
Dalichi Sankyo
Allergan
Takeda Pharmaceutical
AMAG Pharmaceuticals
Pharmacosmos
Luitpold Pharmaceuticals
Among other players domestic and global, Intravenous (IV) Iron Drugs market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Intravenous (IV) Iron Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Intravenous (IV) Iron Drugs, with price, sales, revenue and global market share of Intravenous (IV) Iron Drugs in 2018 and 2019.
Chapter 3, the Intravenous (IV) Iron Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Intravenous (IV) Iron Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Intravenous (IV) Iron Drugs market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Intravenous (IV) Iron Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Intravenous (IV) Iron Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Intravenous (IV) Iron Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Ferric Carboxymaltose
1.2.3 Iron Sucrose
1.2.4 Iron Dextran
1.2.5 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Intravenous (IV) Iron Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Nephrology
1.3.3 Gynecology & Obstetrics
1.3.4 Gastroenterology
1.3.5 Oncology
1.3.6 Cardiology
1.3.7 Others
1.4 Overview of Global Intravenous (IV) Iron Drugs Market
1.4.1 Global Intravenous (IV) Iron Drugs Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Sanofi US
2.1.1 Sanofi US Details
2.1.2 Sanofi US Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Sanofi US SWOT Analysis
2.1.4 Sanofi US Product and Services
2.1.5 Sanofi US Intravenous (IV) Iron Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Dalichi Sankyo
2.2.1 Dalichi Sankyo Details
2.2.2 Dalichi Sankyo Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Dalichi Sankyo SWOT Analysis
2.2.4 Dalichi Sankyo Product and Services
2.2.5 Dalichi Sankyo Intravenous (IV) Iron Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Allergan
2.3.1 Allergan Details
2.3.2 Allergan Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Allergan SWOT Analysis
2.3.4 Allergan Product and Services
2.3.5 Allergan Intravenous (IV) Iron Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Takeda Pharmaceutical
2.4.1 Takeda Pharmaceutical Details
2.4.2 Takeda Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Takeda Pharmaceutical SWOT Analysis
2.4.4 Takeda Pharmaceutical Product and Services
2.4.5 Takeda Pharmaceutical Intravenous (IV) Iron Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 AMAG Pharmaceuticals
2.5.1 AMAG Pharmaceuticals Details
2.5.2 AMAG Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 AMAG Pharmaceuticals SWOT Analysis
2.5.4 AMAG Pharmaceuticals Product and Services
2.5.5 AMAG Pharmaceuticals Intravenous (IV) Iron Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Pharmacosmos
2.6.1 Pharmacosmos Details
2.6.2 Pharmacosmos Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Pharmacosmos SWOT Analysis
2.6.4 Pharmacosmos Product and Services
2.6.5 Pharmacosmos Intravenous (IV) Iron Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Luitpold Pharmaceuticals
2.7.1 Luitpold Pharmaceuticals Details
2.7.2 Luitpold Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Luitpold Pharmaceuticals SWOT Analysis
2.7.4 Luitpold Pharmaceuticals Product and Services
2.7.5 Luitpold Pharmaceuticals Intravenous (IV) Iron Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Intravenous (IV) Iron Drugs Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Intravenous (IV) Iron Drugs Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Intravenous (IV) Iron Drugs Manufacturer Market Share in 2019
3.3.2 Top 6 Intravenous (IV) Iron Drugs Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Intravenous (IV) Iron Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Intravenous (IV) Iron Drugs Sales and Market Share by Regions (2015-2020)
4.1.2 Global Intravenous (IV) Iron Drugs Revenue and Market Share by Regions (2015-2020)
4.2 North America Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
4.3 Europe Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
4.5 South America Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Intravenous (IV) Iron Drugs Sales, Revenue and Market Share by Country
5.1.1 North America Intravenous (IV) Iron Drugs Sales and Market Share by Country (2015-2020)
5.1.2 North America Intravenous (IV) Iron Drugs Revenue and Market Share by Country (2015-2020)
5.2 United States Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
5.3 Canada Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
5.4 Mexico Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Intravenous (IV) Iron Drugs Sales, Revenue and Market Share by Country
6.1.1 Europe Intravenous (IV) Iron Drugs Sales and Market Share by Country (2015-2020)
6.1.2 Europe Intravenous (IV) Iron Drugs Revenue and Market Share by Country (2015-2020)
6.2 Germany Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
6.3 UK Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
6.4 France Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
6.5 Russia Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
6.6 Italy Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Intravenous (IV) Iron Drugs Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Intravenous (IV) Iron Drugs Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Intravenous (IV) Iron Drugs Revenue and Market Share by Regions (2015-2020)
7.2 China Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
7.3 Japan Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
7.4 Korea Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
7.5 India Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
7.7 Australia Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Intravenous (IV) Iron Drugs Sales, Revenue and Market Share by Country
8.1.1 South America Intravenous (IV) Iron Drugs Sales and Market Share by Country (2015-2020)
8.1.2 South America Intravenous (IV) Iron Drugs Revenue and Market Share by Country (2015-2020)
8.2 Brazil Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
8.3 Argentina Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Intravenous (IV) Iron Drugs Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Intravenous (IV) Iron Drugs Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Intravenous (IV) Iron Drugs Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
9.3 Turkey Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
9.4 Egypt Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
9.5 South Africa Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Intravenous (IV) Iron Drugs Sales and Market Share by Type (2015-2020)
10.2 Global Intravenous (IV) Iron Drugs Revenue and Market Share by Type (2015-2020)
10.3 Global Intravenous (IV) Iron Drugs Price by Type (2015-2020)
11 Global Intravenous (IV) Iron Drugs Market Segment by Application
11.1 Global Intravenous (IV) Iron Drugs Sales Market Share by Application (2015-2020)
11.2 Global Intravenous (IV) Iron Drugs Revenue Market Share by Application (2015-2020)
11.3 Global Intravenous (IV) Iron Drugs Price by Application (2015-2020)
12 Market Forecast
12.1 Global Intravenous (IV) Iron Drugs Sales, Revenue and Growth Rate (2021-2025)
12.2 Intravenous (IV) Iron Drugs Market Forecast by Regions (2021-2025)
12.2.1 North America Intravenous (IV) Iron Drugs Market Forecast (2021-2025)
12.2.2 Europe Intravenous (IV) Iron Drugs Market Forecast (2021-2025)
12.2.3 Asia-Pacific Intravenous (IV) Iron Drugs Market Forecast (2021-2025)
12.2.4 South America Intravenous (IV) Iron Drugs Market Forecast (2021-2025)
12.2.5 Middle East & Africa Intravenous (IV) Iron Drugs Market Forecast (2021-2025)
12.3 Intravenous (IV) Iron Drugs Market Forecast by Type (2021-2025)
12.3.1 Global Intravenous (IV) Iron Drugs Sales Forecast by Type (2021-2025)
12.3.2 Global Intravenous (IV) Iron Drugs Market Share Forecast by Type (2021-2025)
12.4 Intravenous (IV) Iron Drugs Market Forecast by Application (2021-2025)
12.4.1 Global Intravenous (IV) Iron Drugs Sales Forecast by Application (2021-2025)
12.4.2 Global Intravenous (IV) Iron Drugs Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Intravenous (IV) Iron Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Intravenous (IV) Iron Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Intravenous (IV) Iron Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Sanofi US Basic Information, Manufacturing Base and Competitors
Table 8. Sanofi US Intravenous (IV) Iron Drugs Major Business
Table 9. Sanofi US Intravenous (IV) Iron Drugs Total Revenue (USD Million) (2017-2018)
Table 10. Sanofi US SWOT Analysis
Table 11. Sanofi US Intravenous (IV) Iron Drugs Product and Services
Table 12. Sanofi US Intravenous (IV) Iron Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Dalichi Sankyo Basic Information, Manufacturing Base and Competitors
Table 14. Dalichi Sankyo Intravenous (IV) Iron Drugs Major Business
Table 15. Dalichi Sankyo Intravenous (IV) Iron Drugs Total Revenue (USD Million) (2017-2018)
Table 16. Dalichi Sankyo SWOT Analysis
Table 17. Dalichi Sankyo Intravenous (IV) Iron Drugs Product and Services
Table 18. Dalichi Sankyo Intravenous (IV) Iron Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Allergan Basic Information, Manufacturing Base and Competitors
Table 20. Allergan Intravenous (IV) Iron Drugs Major Business
Table 21. Allergan Intravenous (IV) Iron Drugs Total Revenue (USD Million) (2017-2018)
Table 22. Allergan SWOT Analysis
Table 23. Allergan Intravenous (IV) Iron Drugs Product and Services
Table 24. Allergan Intravenous (IV) Iron Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Takeda Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 26. Takeda Pharmaceutical Intravenous (IV) Iron Drugs Major Business
Table 27. Takeda Pharmaceutical Intravenous (IV) Iron Drugs Total Revenue (USD Million) (2017-2018)
Table 28. Takeda Pharmaceutical SWOT Analysis
Table 29. Takeda Pharmaceutical Intravenous (IV) Iron Drugs Product and Services
Table 30. Takeda Pharmaceutical Intravenous (IV) Iron Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. AMAG Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 32. AMAG Pharmaceuticals Intravenous (IV) Iron Drugs Major Business
Table 33. AMAG Pharmaceuticals Intravenous (IV) Iron Drugs Total Revenue (USD Million) (2017-2018)
Table 34. AMAG Pharmaceuticals SWOT Analysis
Table 35. AMAG Pharmaceuticals Intravenous (IV) Iron Drugs Product and Services
Table 36. AMAG Pharmaceuticals Intravenous (IV) Iron Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Pharmacosmos Basic Information, Manufacturing Base and Competitors
Table 38. Pharmacosmos Intravenous (IV) Iron Drugs Major Business
Table 39. Pharmacosmos Intravenous (IV) Iron Drugs Total Revenue (USD Million) (2017-2018)
Table 40. Pharmacosmos SWOT Analysis
Table 41. Pharmacosmos Intravenous (IV) Iron Drugs Product and Services
Table 42. Pharmacosmos Intravenous (IV) Iron Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Luitpold Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 44. Luitpold Pharmaceuticals Intravenous (IV) Iron Drugs Major Business
Table 45. Luitpold Pharmaceuticals Intravenous (IV) Iron Drugs Total Revenue (USD Million) (2017-2018)
Table 46. Luitpold Pharmaceuticals SWOT Analysis
Table 47. Luitpold Pharmaceuticals Intravenous (IV) Iron Drugs Product and Services
Table 48. Luitpold Pharmaceuticals Intravenous (IV) Iron Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Global Intravenous (IV) Iron Drugs Sales by Manufacturer (2018-2019) (K Units)
Table 50. Global Intravenous (IV) Iron Drugs Revenue by Manufacturer (2018-2019) (USD Million)
Table 51. Global Intravenous (IV) Iron Drugs Sales by Regions (2015-2020) (K Units)
Table 52. Global Intravenous (IV) Iron Drugs Sales Market Share by Regions (2015-2020)
Table 53. Global Intravenous (IV) Iron Drugs Revenue by Regions (2015-2020) (USD Million)
Table 54. North America Intravenous (IV) Iron Drugs Sales by Countries (2015-2020) (K Units)
Table 55. North America Intravenous (IV) Iron Drugs Sales Market Share by Countries (2015-2020)
Table 56. North America Intravenous (IV) Iron Drugs Revenue by Countries (2015-2020) (USD Million)
Table 57. North America Intravenous (IV) Iron Drugs Revenue Market Share by Countries (2015-2020)
Table 58. Europe Intravenous (IV) Iron Drugs Sales by Countries (2015-2020) (K Units)
Table 59. Europe Intravenous (IV) Iron Drugs Sales Market Share by Countries (2015-2020)
Table 60. Europe Intravenous (IV) Iron Drugs Revenue by Countries (2015-2020) (USD Million)
Table 61. Asia-Pacific Intravenous (IV) Iron Drugs Sales by Regions (2015-2020) (K Units)
Table 62. Asia-Pacific Intravenous (IV) Iron Drugs Sales Market Share by Regions (2015-2020)
Table 63. Asia-Pacific Intravenous (IV) Iron Drugs Revenue by Regions (2015-2020) (USD Million)
Table 64. South America Intravenous (IV) Iron Drugs Sales by Countries (2015-2020) (K Units)
Table 65. South America Intravenous (IV) Iron Drugs Sales Market Share by Countries (2015-2020)
Table 66. South America Intravenous (IV) Iron Drugs Revenue by Countries (2015-2020) (USD Million)
Table 67. South America Intravenous (IV) Iron Drugs Revenue Market Share by Countries (2015-2020)
Table 68. Middle East & Africa Intravenous (IV) Iron Drugs Sales by Countries (2015-2020) (K Units)
Table 69. Middle East & Africa Intravenous (IV) Iron Drugs Sales Market Share by Countries (2015-2020)
Table 70. Middle East & Africa Intravenous (IV) Iron Drugs Revenue by Countries (2015-2020) (USD Million)
Table 71. Middle East & Africa Intravenous (IV) Iron Drugs Revenue Market Share by Countries (2015-2020)
Table 72. Global Intravenous (IV) Iron Drugs Sales by Type (2015-2020) (K Units)
Table 73. Global Intravenous (IV) Iron Drugs Sales Share by Type (2015-2020)
Table 74. Global Intravenous (IV) Iron Drugs Revenue by Type (2015-2020) (USD Million)
Table 75. Global Intravenous (IV) Iron Drugs Revenue Share by Type (2015-2020)
Table 76. Global Intravenous (IV) Iron Drugs Sales by Application (2015-2020) (K Units)
Table 77. Global Intravenous (IV) Iron Drugs Sales Share by Application (2015-2020)
Table 78. Global Intravenous (IV) Iron Drugs Sales Forecast by Regions (2021-2025) (K Units)
Table 79. Global Intravenous (IV) Iron Drugs Market Share Forecast by Regions (2021-2025)
Table 80. Global Intravenous (IV) Iron Drugs Sales Forecast by Type (2021-2025) (K Units)
Table 81. Global Intravenous (IV) Iron Drugs Market Share Forecast by Type (2021-2025)
Table 82. Global Intravenous (IV) Iron Drugs Sales Forecast by Application (2021-2025)
Table 83. Global Intravenous (IV) Iron Drugs Market Share Forecast by Application (2021-2025)
Table 84. Direct Channel Pros & Cons
Table 85. Indirect Channel Pros & Cons
Table 86. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Intravenous (IV) Iron Drugs Picture
Figure 2. Global Sales Market Share of Intravenous (IV) Iron Drugs by Type in 2019
Figure 3. Ferric Carboxymaltose Picture
Figure 4. Iron Sucrose Picture
Figure 5. Iron Dextran Picture
Figure 6. Others Picture
Figure 7. Intravenous (IV) Iron Drugs Sales Market Share by Application in 2018
Figure 8. Nephrology Picture
Figure 9. Gynecology & Obstetrics Picture
Figure 10. Gastroenterology Picture
Figure 11. Oncology Picture
Figure 12. Cardiology Picture
Figure 13. Others Picture
Figure 14. Global Intravenous (IV) Iron Drugs Market Status and Outlook (2015-2025) (USD Million)
Figure 15. United States Intravenous (IV) Iron Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Canada Intravenous (IV) Iron Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Mexico Intravenous (IV) Iron Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Germany Intravenous (IV) Iron Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 19. France Intravenous (IV) Iron Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 20. UK Intravenous (IV) Iron Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Russia Intravenous (IV) Iron Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Italy Intravenous (IV) Iron Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 23. China Intravenous (IV) Iron Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Japan Intravenous (IV) Iron Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Korea Intravenous (IV) Iron Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 26. India Intravenous (IV) Iron Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Southeast Asia Intravenous (IV) Iron Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Australia Intravenous (IV) Iron Drugs Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 29. Brazil Intravenous (IV) Iron Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Egypt Intravenous (IV) Iron Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 31. Saudi Arabia Intravenous (IV) Iron Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 32. South Africa Intravenous (IV) Iron Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 33. Turkey Intravenous (IV) Iron Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 34. Global Intravenous (IV) Iron Drugs Sales Market Share by Manufacturer in 2019
Figure 35. Global Intravenous (IV) Iron Drugs Revenue Market Share by Manufacturer in 2019
Figure 36. Top 3 Intravenous (IV) Iron Drugs Manufacturer (Revenue) Market Share in 2019
Figure 37. Top 6 Intravenous (IV) Iron Drugs Manufacturer (Revenue) Market Share in 2019
Figure 38. Key Manufacturer Market Share Trend
Figure 39. Global Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 40. Global Intravenous (IV) Iron Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 41. Global Intravenous (IV) Iron Drugs Revenue Market Share by Regions (2015-2020)
Figure 42. Global Intravenous (IV) Iron Drugs Revenue Market Share by Regions in 2018
Figure 43. North America Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
Figure 44. Europe Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
Figure 45. Asia-Pacific Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
Figure 46. South America Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
Figure 47. Middle East & Africa Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020)
Figure 48. North America Intravenous (IV) Iron Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 49. North America Intravenous (IV) Iron Drugs Sales Market Share by Countries (2015-2020)
Figure 50. North America Intravenous (IV) Iron Drugs Sales Market Share by Countries in 2018
Figure 51. North America Intravenous (IV) Iron Drugs Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 52. North America Intravenous (IV) Iron Drugs Revenue Market Share by Countries in 2018
Figure 53. United States Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 54. Canada Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 55. Mexico Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 56. Europe Intravenous (IV) Iron Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 57. Europe Intravenous (IV) Iron Drugs Revenue Market Share by Countries (2015-2020)
Figure 58. Europe Intravenous (IV) Iron Drugs Revenue Market Share by Countries in 2019
Figure 59. Germany Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 60. UK Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 61. France Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 62. Russia Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 63. Italy Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 64. Asia-Pacific Intravenous (IV) Iron Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 65. Asia-Pacific Intravenous (IV) Iron Drugs Sales Market Share by Regions 2019
Figure 66. Asia-Pacific Intravenous (IV) Iron Drugs Revenue Market Share by Regions 2019
Figure 67. China Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 68. Japan Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 69. Korea Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 70. India Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 71. Southeast Asia Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 72. South America Intravenous (IV) Iron Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 73. South America Intravenous (IV) Iron Drugs Sales Market Share by Countries in 2019
Figure 74. South America Intravenous (IV) Iron Drugs Revenue Market Share by Countries in 2019
Figure 75. Brazil Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 76. Argentina Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 77. Middle East and Africa Intravenous (IV) Iron Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 78. Middle East and Africa Intravenous (IV) Iron Drugs Sales Market Share by Countries in 2019
Figure 79. Middle East and Africa Intravenous (IV) Iron Drugs Revenue Market Share by Countries (2015-2020)
Figure 80. Middle East and Africa Intravenous (IV) Iron Drugs Revenue Market Share by Countries in 2019
Figure 81. Saudi Arabia Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 82. Egypt Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 83. Turkey Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 84. South Africa Intravenous (IV) Iron Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 85. Global Intravenous (IV) Iron Drugs Sales and Growth Rate (2021-2025) (K Units)
Figure 86. Global Intravenous (IV) Iron Drugs Revenue and Growth Rate (2021-2025) (USD Million)
Figure 87. North America Sales Intravenous (IV) Iron Drugs Market Forecast (2021-2025) (K Units)
Figure 88. Europe Sales Intravenous (IV) Iron Drugs Market Forecast (2021-2025) (K Units)
Figure 89. Asia-Pacific Sales Intravenous (IV) Iron Drugs Market Forecast (2021-2025) (K Units)
Figure 90. South America Sales Intravenous (IV) Iron Drugs Market Forecast (2021-2025) (K Units)
Figure 91. Middle East & Africa Sales Intravenous (IV) Iron Drugs Market Forecast (2021-2025) (K Units)
Figure 92. Sales Channel: Direct Channel vs Indirect Channel
静脈内鉄薬の世界市場（～2026年） Iron is an essential element as it plays an important role in many vital biological processes such as the synthesis of heme which forms the basis of hemoglobin (Hb) the oxygen-carrying protein of the blood, the formation of myoglobin, energy metabolism, neurotransmitter production, the formation of …- 鉄剤の世界市場（～2026年） Iron is required to transport oxygen through haemoglobin in red blood cells (RBCs) and oxidize cells through cytochrome. Iron deficiency is a common cause of anaemia. Iron drugs are used to treat people with iron deficiency. In terms of geographic regions, the North Americas accounted for the major …
- 静脈内（IV）鉄剤の世界市場（～2026年） Iron supplements are available in two forms: oral and intravenous. Intravenous iron preparations are superior to oral supplements, as these lead to higher and faster increase in iron and Hb levels. Oral supplements have disadvantages such as GI adverse events, poor adherence, poor gastrointestinal a…
- 水素還元鉄粉の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The Hydrogen Reduced Iron Powder market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimi…
- ホットブリケットアイアン（HBI）の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The Hot Briquetted Iron (HBI) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizat…